Abstract:Gliomas, a type of brain tumor originating from glial cells, comprise a heterogenous group of neoplasms. High-grade gliomas, in particular, present significant therapeutic challenges in the clinic. Unlike other solid tumors, the heterogenous glioma microenvironment is heavily enriched with tumor associated suppressor cells including myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs), which can account for 30-40% of the cellular composition1. These pro-tumorigenic myeloid cells are thought to contribute to the resistance of glioma to immunotherapy. Efforts to target the suppressive nature of these dominating cell types are in development to yield more therapeutic options for patients with these devastating diseases. Constitutive activation of STAT3 in gliomas has been associated with increased tumor progression and reduced immune response. We have observed in other cancer models that a phenotypic switch occurs from STAT3 pathway activation in 3D spheroid culture to STAT3 inactivation when cultured in 2D. Therefore, we sought to determine the role of STAT3 activation and its role in the interplay between glioma and their immune suppressive environment using a 3D spheroid model. We modified our commercially available test platform, 3D-PredictTM Glioma, such that it is conducive to monitoring immune cell function. Newly diagnosed treatment naive primary samples from HGG patients were dissociated and cryogenically preserved and banked. Samples were profiled for the abundance of tumor associated suppressive myeloid cells using flow cytometry. We determined that relative proportions of tumor suppressor cells were detectable and varied across HGG primary patient samples with TAMs being the predominate immune cell type identified. Pro-tumorigenic TAM markers including CD163 and CD206 were correlated with temozolomide response and were associated with poor patient prognosis. When we evaluated the role of p-STAT in HGG primary samples, p-STAT was detected at baseline and abundance was related back to the presence of tumor associated immune suppressor cells. The impact of STAT3 signaling blockade by the inhibitor WP1066 was determined ex vivo, and efficacy was related back to MGMT promotor methylation status and patient clinical outcome. We detected shifts in cytokine signatures following treatment of HGG 3D spheroid models with WP1066 which are known to target tumor associated suppressor cell functions. This work demonstrates the critical role suppressive immune cells play in HGG clinical response. Given p-STAT can be altered in 2D culture compared to 3D culture, ex vivo therapeutic response profiling of HGG samples is necessary using the more physiologically relevant spheroid culture model. 1.Hambardzumyan et al. The role of microglia and macrophages in glioma maintenance and progression. Nat. Neurosci. 19, 20-27 (2016). Citation Format: Katy A. Lassahn, Ashley K. Elrod, Teresa M. DesRochers, Kathryn M. Appleton. Ex vivo pharmacologic inhibition of STAT3 effectively targets tumor and tumor associated suppressor cells in high-grade glioma 3D spheroids [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5287.

Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice

The role of STAT3 activation in modulating the immune microenvironment of GBM

STAT3 Signaling Pathway Regulates Glioma Stem Cells Induced Host Macrophage Malignance

Abstract 5287: Ex vivo pharmacologic inhibition of STAT3 effectively targets tumor and tumor associated suppressor cells in high-grade glioma 3D spheroids

Signal Transducer and Activator of Transcription 3 Promotes Angiogenesis and Drives Malignant Progression in Glioma

Targeting Stat3 Suppresses Growth of U251 Cell-Derived Tumours in Nude Mice

Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy

Antitumor Activity Of Novel Pyrazole-Based Small Molecular Inhibitors Of The Stat3 Pathway In Patient Derived High Grade Glioma Cells

Loss of SOCS3 in myeloid cells prolongs survival in a syngeneic model of glioma

Knockdown of STAT3 Expression by RNAi Suppresses Growth and Induces Apoptosis and Differentiation in Glioblastoma Stem Cells.

miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma

Glioma Stem-Like Cells Evade Interferon Suppression Through MBD3/NuRD Complex-Mediated STAT1 Downregulation

STAT3 Silencing with Lentivirus Inhibits Growth and Induces Apoptosis and Differentiation of U251 Cells

Inhibition of STAT3 Reduces Astrocytoma Cell Invasion and Constitutive Activation of STAT3 Predicts Poor Prognosis in Human Astrocytoma.

Inhibition of STAT3 Using Shrna Inhibits Thymidine Kinase (TK) Mediated Glioma Cell Death in Vitro and Abrogates Flt3L and TK Dependent Tumor Regression in Vivo.

Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity

Assessing the Role of STAT3 in DC Differentiation and Autologous DC Immunotherapy in Mouse Models of GBM

STAT3 is a Biologically Relevant Therapeutic Target in H3K27M-mutant Diffuse Midline Glioma

STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells

Effect of signal transducer and activators of transcription 3 on migration of human glioblastoma cells

STAT3 drives the malignant progression of low-grade gliomas through modulating the expression of STAT1, FOXO1, and MYC